SynthesisBMC cancer2025

Optimal early endpoint for second-line or subsequent immune checkpoint inhibitors in previously treated advanced solid cancers: a systematic review.

Jingqiu Li et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.